159 related articles for article (PubMed ID: 23764770)
21. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
22. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Reddy N; Holkova B; Ottman E; Czuczman MS
Clin Cancer Res; 2005 Aug; 11(16):5984-92. PubMed ID: 16115943
[TBL] [Abstract][Full Text] [Related]
24. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
Kita A; Mitsuoka K; Kaneko N; Nakata M; Yamanaka K; Jitsuoka M; Miyoshi S; Noda A; Mori M; Nakahara T; Sasamata M
J Pharmacol Exp Ther; 2012 Oct; 343(1):178-83. PubMed ID: 22787117
[TBL] [Abstract][Full Text] [Related]
25. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
[TBL] [Abstract][Full Text] [Related]
26. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.
Dakappagari N; Ho SN; Gascoyne RD; Ranuio J; Weng AP; Tangri S
Cytometry B Clin Cytom; 2012 Mar; 82(2):112-9. PubMed ID: 22076940
[TBL] [Abstract][Full Text] [Related]
27. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma.
Zinzani PL
Hematol J; 2004; 5 Suppl 1():S38-49. PubMed ID: 15079152
[TBL] [Abstract][Full Text] [Related]
30. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
[TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
32. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
Pathan NI; Chu P; Hariharan K; Cheney C; Molina A; Byrd J
Blood; 2008 Feb; 111(3):1594-602. PubMed ID: 18032710
[TBL] [Abstract][Full Text] [Related]
33. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
34. Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Paschal BR
Leuk Lymphoma; 2003 Apr; 44(4):731-3. PubMed ID: 12769354
[TBL] [Abstract][Full Text] [Related]
35. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Czuczman MS; Fallon A; Mohr A; Stewart C; Bernstein ZP; McCarthy P; Skipper M; Brown K; Miller K; Wentling D; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-López AJ; Bernstein SH
Semin Oncol; 2002 Feb; 29(1 Suppl 2):36-40. PubMed ID: 11842387
[TBL] [Abstract][Full Text] [Related]
36. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
Cooper AC; Karp RM; Clark EJ; Taghizadeh NR; Hoyt JG; Labenski MT; Murray MJ; Hannig G; Westlin WF; Thompson CD
Clin Cancer Res; 2006 Apr; 12(8):2583-90. PubMed ID: 16638869
[TBL] [Abstract][Full Text] [Related]
37. Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma.
Yan JS; Chen XY; Li WP; Yang Y; Song ZL
Ai Zheng; 2009 Feb; 28(2):181-3. PubMed ID: 19550134
[TBL] [Abstract][Full Text] [Related]
38. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
40. Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma.
Xiao X; Li H; Jin H; Jin J; Yu M; Ma C; Tong Y; Zhou L; Lei H; Xu H; Zhang W; Liu W; Wu Y
Cell Death Dis; 2017 Sep; 8(9):e3050. PubMed ID: 28906487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
